Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 5, 2025Open Access

Supplementary Figure 6 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

View Full Paper
Ask AI
Bookmark
Share

Authors

LRLuis Gerardo Rodríguez‐LobatoOCOriol CardúsJMJoan Mañé-Pujol

Discussion

Loading...

Member takes

Overview

Observational analysis reveals effective control of myeloma in tumor cells with limited BCMA, indicating dual-targeting benefits.

Key Points

  • The dual-targeting approach effectively controls myeloma even with limited BCMA expression on tumor cells.
  • Key evidence shows that bicistronic CAR T cells against BCMA and CD229 can target myeloma effectively despite lower BCMA levels.
  • The method utilized involves examining BCMA and CD229 antigen expression on wild-type and BCMA knockout tumor cells.
  • These findings suggest potential advancements in myeloma treatments, especially for cases with limited BCMA expression.

Cite This Study

Rodríguez‐Lobato et al. (2025) studied this question.

synapsesocial.com/papers/68c23a2cb210217d6477fb2dhttps://doi.org/10.1158/2326-6066.30029623
View Full Paper
Ask AI
Bookmark
Share